
Trevena TRVN
Quarterly report 2024-Q3
added 11-07-2024
Trevena Depreciation & Amortization 2011-2026 | TRVN
Annual Depreciation & Amortization Trevena
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 334 K | 382 K | 428 K | 477 K | 562 K | 645 K | 490 K | 246 K | 208 K | 239 K | 707 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 707 K | 208 K | 429 K |
Quarterly Depreciation & Amortization Trevena
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 88 K | - | - | - | 82 K | - | 300 K | 210 K | 105 K | - | 322 K | 214 K | 108 K | - | 368 K | 257 K | 128 K | - | 431 K | 297 K | 149 K | - | 496 K | 340 K | 171 K | - | 345 K | 158 K | 79 K | - | 180 K | 119 K | 58 K | - | 155 K | 104 K | 52.5 K | - | 185 K | 142 K | 106 K | - | 547 K | 375 K | 193 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 547 K | 52.5 K | 215 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Akari Therapeutics, Plc
AKTX
|
14 K | $ 3.54 | -20.81 % | $ 238 B | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 330.34 | 3.6 % | $ 43.3 B | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
1 K | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Aptorum Group Limited
APM
|
1.13 M | $ 0.89 | -4.33 % | $ 4.85 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
AbbVie
ABBV
|
762 M | $ 206.69 | -1.01 % | $ 366 B | ||
|
Aquestive Therapeutics
AQST
|
548 K | $ 4.09 | -0.97 % | $ 437 M | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
AbCellera Biologics
ABCL
|
18.4 M | $ 3.39 | -3.69 % | $ 1.01 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
3.02 M | $ 8.22 | 2.37 % | $ 225 M | ||
|
Ardelyx
ARDX
|
3.06 M | $ 5.97 | 0.51 % | $ 1.44 B | ||
|
Cerevel Therapeutics Holdings
CERE
|
5.63 M | - | - | $ 7.29 B | ||
|
Akebia Therapeutics
AKBA
|
1.27 M | $ 1.32 | -4.35 % | $ 339 M |